The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium

被引:0
作者
Fraeyman, Jessica [1 ]
Van Hal, Guido [1 ]
Godman, Brian [2 ,3 ]
Beutels, Philippe [4 ]
机构
[1] Univ Antwerp, Res Grp Med Sociol & Publ Hlth, B-2020 Antwerp, Belgium
[2] Mario Negri Inst Pharmacol Res, I-20156 Milan, Italy
[3] Karolinska Inst, Karolinska Univ Hosp Huddinge, Dept Lab Med, Div Clin Pharmacol, SE-14186 Stockholm, Sweden
[4] Univ Antwerp, Ctr Hlth Econ Res & Modeling Infect Dis, Vaccine & Infect Dis Inst, B-2020 Antwerp, Belgium
关键词
Belgium; demand-side measures; drug utilization studies; generics; pharmaceuticals; proton pump inhibitors; reference pricing; statins; MULTIPLE INITIATIVES; GENERIC MEDICINE; LOW PRICES; EFFICIENCY; ENHANCE; POLICIES; EUROPE; QUALITY; IMPACT; RISK;
D O I
10.1586/ERP.12.88
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Proton pump inhibitors (PPIs) and statins have been among the top three most prescribed medicines in Belgium for more than a decade. Multiple demand-side measures have been introduced to improve rational prescribing generally, as well as for these two classes. Objectives: First, assessing the influence of general and specific reforms introduced in Belgium since 1997 on utilization and expenditure of the PPIs and statins. Second, suggesting additional measures to further improve rational prescribing based on experiences in other European countries. Methods: A retrospective observational study for assessing the influence of multiple initiatives in Belgium on utilization and expenditure of the PPIs and statins from 1997 to 2009 was carried out. Data were extracted from the administrative database Pharmanet. Utilization was measured in terms of defined daily doses (DDDs) and DDDs/thousand inhabitants per day. Results: Multiple reforms, including co-payments and reference pricing, appreciably enhanced rational prescribing for both PPIs and statins following generic availability. There was an eightfold increase in PPI utilization between 1997 and 2009, but only a twofold increase in reimbursed expenditure, helped by decreasing expenditure/DDD for the PPIs from (sic)1.91 in 1997 to (sic)0.52 in 2009. Similarly, a 20-fold increase was observed in statin utilization between 1997 and 2009, but only a fivefold increase in reimbursed expenditure, helped again by reimbursed expenditure/DDD decreasing from (sic)2.05 in 1997 to (sic)0.57 in 2009. Reduced co-payments for larger packs enhanced their prescription. Conclusion: Multiple reforms influenced utilization patterns and expenditure for the PPIs and statins, as well as the pack sizes dispensed. Additional demand-side measures are needed to further enhance rational prescribing, which can build on the experiences in other countries. These can be potentially transferred to other classes.
引用
收藏
页码:141 / 151
页数:11
相关论文
共 57 条
  • [1] Abuelkhair M, 2012, EXPERT REV PHARM OUT, V12, P115, DOI [10.1586/ERP.11.90, 10.1586/erp.11.90]
  • [2] [Anonymous], 2007, BELGIAN STATE MONITO
  • [3] Austvoll-Dahlgren A, 2009, COCHRANE DB SYST REV, V23
  • [4] Using clinical evidence - Having the evidence in your hand is just a start - but a good one
    Barton, S
    [J]. BRITISH MEDICAL JOURNAL, 2001, 322 (7285) : 503 - 504
  • [5] Bennie M, 2012, EXPERT REV PHARM OUT, V12, P125, DOI [10.1586/ERP.11.98, 10.1586/erp.11.98]
  • [6] Bero LA, 1998, BMJ-BRIT MED J, V317, P465
  • [7] Borgermans L, 2010, KCE REPORTS C
  • [8] Coma Anna, 2009, Expert Rev Pharmacoecon Outcomes Res, V9, P569, DOI 10.1586/erp.09.58
  • [9] De Graeve D, 2006, OWN PAYMENTS BELGIAN, P240
  • [10] DeSwaef A., 2008, PHARM PRICING REIMBU